CompletedPhase 2NCT01266460
Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer
Studying Adenocarcinoma of the cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gynecologic Oncology Group
- Principal Investigator
- Warner K Huh, MDNRG Oncology
- Intervention
- Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001(biological)
- Enrollment
- 54 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2011 – 2018
Study locations (24)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- Los Angeles County-USC Medical Center, Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- UCSF Medical Center-Mount Zion, San Francisco, California, United States
- UCSF Medical Center-Mission Bay, San Francisco, California, United States
- Memorial Health University Medical Center, Savannah, Georgia, United States
- University of Kansas Cancer Center, Kansas City, Kansas, United States
- Sinai Hospital of Baltimore, Baltimore, Maryland, United States
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Montefiore Medical Center-Einstein Campus, The Bronx, New York, United States
- Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States
- +9 more locations on ClinicalTrials.gov
Collaborators
Advaxis, Inc. · National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01266460 on ClinicalTrials.govOther trials for Adenocarcinoma of the cervix uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07276360Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in UgandaUganda Cancer Institute
- RECRUITINGPHASE1NCT07454642AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid TumorsAvacta Life Sciences Ltd
- RECRUITINGPHASE3NCT07061977Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerNational Cancer Institute (NCI)
- RECRUITINGNCT07359586Laryngopharyngeal Injury After Endotracheal Intubation Under General AnesthesiaZhejiang University
- RECRUITINGPHASE1NCT07020117A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsAktis Oncology, Inc.
- RECRUITINGPHASE2NCT06654011IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 TrialUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07153952RT for Adenocarcinoma/Adenosquamous CarcinomaPeking Union Medical College Hospital
- RECRUITINGNCT06733740Ultrasound-guided Thermal Ablation for Papillary Thyroid CarcinomaChinese PLA General Hospital